“This bill would require the Alabama Medicaid Agency to cover screening and would also regulate how Medicaid covers prescription drugs used to treat postpartum depression,” the legislation states.

Craske and her colleagues hypothesized that targeting this mechanism for reward sensitivity could help strengthen affected ...

Supernus Pharmaceuticals said on Tuesday its depression treatment trial failed to meet the main goal of reduction in depressive symptoms, sending its shares down 22% aftermarket.

Depression impacts overall health, accelerating the onset of chronic conditions by 30%. A study found that those with a ...

Major depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing to treatment-resistant depression (TRD).

The company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...

Supernus' SPN-820 Phase 2b study in treatment-resistant depression failed to meet its primary endpoint, prompting further ...

US CNS specialist Supernus Pharmaceuticals has announced that its Phase IIb study of SPN-820 in adults with ...

Researchers have debunked key beliefs about addiction, like that a person must hit "rock bottom" before having treatment or ...

After SPN-820's failure, Supernus is relying on its non-stimulant ADHD drug Qelbree and the recently approved Parkinson’s ...

New postpartum depression findings could lead to a blood test to identify women at risk and possibly even to a preventive treatment.

In the second episode of The Deep End, listeners hear what it’s like to live with severe depression and the backstory of an experimental treatment.